Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HaloPolymer is a leading global producer of fluoropolymer products, accounting for approximately 9% of the world market. The company specializes in the manufacture of polytetrafluoroethylene (PTFE), melt-processable fluoroplastics, fluoroelastomers, and high-purity inorganic chemicals. In the healthcare sector, HaloPolymer provides essential medical-grade materials used in the production of life-saving devices such as catheters, vascular grafts, heart patches, and pharmaceutical packaging. Operating major production facilities in Perm and Kirovo-Chepetsk, Russia, the company maintains a robust international presence through its trading subsidiaries in the United States and Europe. HaloPolymer is a key subsidiary of the Uralchem Group, one of the world's largest chemical conglomerates. Its products are recognized for their exceptional chemical resistance, thermal stability, and biocompatibility, making them indispensable for advanced medical and industrial applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HaloPolymer.